Skip directly to search Skip directly to A to Z list Skip directly to page options Skip directly to site content

Volume 14, Number 8—August 2008

Dispatch

Oseltamivir Prescribing in Pharmacy-Benefits Database, United States, 2004–20051

Justin R. Ortiz*2Comments to Author , Laurie Kamimoto*, Ronald E. Aubert†, Jianying Yao†, David K. Shay*, Joseph S. Bresee*, and Robert S. Epstein†
Author affiliations: *Centers for Disease Control and Prevention, Atlanta, GA, USA; †Medco Health Solutions, Inc., Franklin Lakes, New Jersey, USA;

Main Article

Table 1

Anti-influenza drug prescription rates/100,000 enrollees and proportions of all anti-influenza drug prescriptions, United States, weeks 36–44, 2004 and 2005*

Medication Anti-influenza prescription rates/100,000 enrollees of all ages, weeks 36–44
% Total anti-influenza prescriptions
2004 2005 Rate ratio (2005/2004) 95% Confidence interval 2004 2005
Neuraminidase inhibitors
Oseltamivir
27.3
133
4.88
4.79–4.97

36.99
76.89
Zanamivir 0.35 1.39 4.00 3.38–4.75 0.47 0.80
Adamantanes
Amantadine
41.7
36.3
0.87
0.85–0.89

56.53
20.93
Rimantadine 4.43 2.37 0.54 0.50–0.58 6.00 1.37
All anti-influenza drugs 80.0 173.2 2.17 2.14–2.19 100 100

*Sums do not equal 100% because of rounding.

Main Article

1This study was presented, in part, at the Infectious Diseases Society of America annual meeting in Toronto, Ontario, Canada, October 14, 2006, and in poster form at the Options for the Control of Influenza Conference, Toronto, June 17, 2007.

2Current affiliation: University of Washington, Seattle, WA, USA.

TOP